Page 30 - Read Online

Puyana et al. J Transl Genet Genom 2022;6:223-239 https://dx.doi.org/10.20517/jtgg.2021.51 Page 237

two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26. DOI PubMed
43. Hart PC, Rajab IM, Alebraheem M, Potempa LA. C-reactive protein and cancer-diagnostic and therapeutic insights. Front Immunol
2020;11:595835. DOI PubMed PMC
44. Markozannes G, Koutsioumpa C, Cividini S, et al. Global assessment of C-reactive protein and health-related outcomes: an umbrella
review of evidence from observational studies and Mendelian randomization studies. Eur J Epidemiol 2021;36:11-36. DOI PubMed
PMC
45. Guo L, Liu S, Zhang S, et al. C-reactive protein and risk of breast cancer: a systematic review and meta-analysis. Sci Rep
2015;5:10508. DOI PubMed PMC
46. Gunter MJ, Wang T, Cushman M, et al. Circulating adipokines and inflammatory markers and postmenopausal breast cancer risk. J
Natl Cancer Inst 2015;107:djv169. DOI PubMed PMC
47. Price TR, Friedenreich CM, Robson PJ, Li H, Brenner DR. High-sensitivity C-reactive protein, hemoglobin A1c and breast cancer
risk: a nested case-control study from Alberta’s Tomorrow Project cohort. Cancer Causes Control 2020;31:1057-68. DOI PubMed
48. Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-reactive protein and breast cancer risk-systematic literature review
and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomarkers Prev 2015;24:1439-49. DOI PubMed
49. Wu X, Zhang X, Hao Y, Li J. Obesity-related protein biomarkers for predicting breast cancer risk: an overview of systematic reviews.
Breast Cancer 2021;28:25-39. DOI PubMed
50. Arthur RS, Dannenberg AJ, Rohan TE. The association of prediagnostic circulating levels of cardiometabolic markers, testosterone
and sex hormone-binding globulin with risk of breast cancer among normal weight postmenopausal women in the UK Biobank. Int J
Cancer 2021;149:42-57. DOI PubMed
51. Jung SY, Papp JC, Sobel EM, Pellegrini M, Yu H, Zhang ZF. Genetically predicted C-reactive protein associated with
postmenopausal breast cancer risk: interrelation with estrogen and cancer molecular subtypes using mendelian randomization. Front
Oncol 2020;10:630994. DOI PubMed PMC
52. Hong T, Liu A, Cai D, et al. Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status.
Cancer Invest 2013;31:279-85. DOI PubMed
53. Wang J, Lee IM, Tworoger SS, et al. Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-
analysis. Cancer Epidemiol Biomarkers Prev 2015;24:1199-206. DOI PubMed PMC
54. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with
poor prognosis after breast cancer: a cohort study. Breast Cancer Res 2011;13:R55. DOI PubMed PMC
55. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among
breast cancer patients. J Clin Oncol 2009;27:3437-44. DOI PubMed PMC
56. Shimura T, Shibata M, Gonda K, et al. Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer.
Oncol Lett 2019;17:5139-46. DOI PubMed PMC
57. Gathirua-Mwangi WG, Song Y, Monahan PO, Champion VL, Zollinger TW. Associations of metabolic syndrome and C-reactive
protein with mortality from total cancer, obesity-linked cancers and breast cancer among women in NHANES III. Int J Cancer
2018;143:535-42. DOI PubMed PMC
58. Nelson SH, Brasky TM, Patterson RE, et al. The association of the C-reactive protein inflammatory biomarker with breast cancer
incidence and mortality in the Women’s Health Initiative. Cancer Epidemiol Biomarkers Prev 2017;26:1100-6. DOI PubMed PMC
59. Tobias DK, Akinkuolie AO, Chandler PD, et al. Markers of inflammation and incident breast cancer risk in the Women’s Health
Study. Am J Epidemiol 2018;187:705-16. DOI PubMed PMC
60. Graff M, Fernández-Rhodes L, Liu S, et al. Generalization of adiposity genetic loci to US Hispanic women. Nutr Diabetes
2013;3:e85. DOI PubMed PMC
61. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science 2007;316:889-94. DOI PubMed PMC
62. Fox CS, Heard-Costa N, Cupples LA, Dupuis J, Vasan RS, Atwood LD. Genome-wide association to body mass index and waist
circumference: the Framingham Heart Study 100K project. BMC Med Genet 2007;8 Suppl 1:S18. DOI PubMed PMC
63. Hinney A, Nguyen TT, Scherag A, et al. Genome wide association (GWA) study for early onset extreme obesity supports the role of
fat mass and obesity associated gene (FTO) variants. PLoS One 2007;2:e1361. DOI PubMed PMC
64. Loos RJ, Yeo GS. The bigger picture of FTO: the first GWAS-identified obesity gene. Nat Rev Endocrinol 2014;10:51-61. DOI
PubMed PMC
65. Liu YJ, Liu XG, Wang L, et al. Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. Hum Mol Genet
2008;17:1803-13. DOI PubMed PMC
66. Thorleifsson G, Walters GB, Gudbjartsson DF, et al. Genome-wide association yields new sequence variants at seven loci that
associate with measures of obesity. Nat Genet 2009;41:18-24. DOI PubMed
67. Willer CJ, Speliotes EK, Loos RJ, et al; Wellcome Trust Case Control Consortium, Genetic Investigation of ANthropometric Traits
Consortium. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet
2009;41:25-34. DOI PubMed PMC
68. Meyre D, Delplanque J, Chèvre JC, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three
new risk loci in European populations. Nat Genet 2009;41:157-9. DOI PubMed
69. Cotsapas C, Speliotes EK, Hatoum IJ, et al; GIANT Consortium. Common body mass index-associated variants confer risk of